20/20 Biolabs, Inc. Common Stock (AIDX)vsMerck & Company Inc (MRK)
AIDX
20/20 Biolabs, Inc. Common Stock
$0.61
-7.75%
HEALTHCARE · Cap: $6.97M
MRK
Merck & Company Inc
$125.40
-2.44%
HEALTHCARE · Cap: $283.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 3565141% more annual revenue ($65.77B vs $1.84M). MRK leads profitability with a 13.6% profit margin vs -279.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).
AIDX
Avoid21
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AIDX.
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$125.40
$44.44 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -354.6% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AIDX
The strongest argument for AIDX centers on Debt/Equity, Price/Book.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
AIDX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.22 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 21/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (AIDX) is an innovative biotechnology firm committed to revolutionizing genomic research and diagnostics through its advanced laboratory services. With a keen focus on enhancing the accuracy and efficiency of genetic testing for clinical and research purposes, the company is poised to be a leader in the molecular diagnostics landscape. By leveraging state-of-the-art technologies, 20/20 Biolabs is strategically positioned to capitalize on the growing demand for personalized medicine and genomic data. Its strong market presence and forward-thinking initiatives underscore a compelling growth outlook within the rapidly evolving biotechnology sector.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?